Moderna Inc Stock Price Target Forecast, (MRNA) Prediction 2022, 2023, 2025, 2030

January 6, 2022

Moderna Share Forecast for January 2022 – Is Now the Time to Invest in MRNA?

Moderna (NASDAQ: MRNA), an American pharmaceutical and biotechnology business, is down today after closing at $215.23 on January 5th (19:59 EST). Moderna will gain if vaccination and booster rates rise as the Omicron version spreads across the United States like wildfire.

Should You Invest in MRNA Stock?

Investors interested in Moderna can look at the company’s latest quarterly financial reports to see how the vaccine affected its operations. It reported $5 billion in sales for the quarter ending September 30, 2021, up from $157 million in the same period in 2020. Moderna also generated $11.3 billion in sales in the first nine months of 2021, up from $232 million in the same time the previous year.

Moderna’s profitability has been outstanding, with a reported net income of $3.3 billion for the quarter ending September 30, 2021, compared to a net loss of $233 million for the same time in 2020. The company’s net income climbed as well, reaching $7.3 billion for the nine months ended September 30th, 2021. These gains will help the company strengthen its cash situation, allowing it to invest in future clinical investigations that might lead to more scientific discoveries or refinement of existing drugs like the COVID-19 vaccine.

Moderna shares, on the other hand, were not immune to the larger market pullbacks that hit high-flying tech equities in November and December. Even if Omicron declines in 2022, there is a strong potential that new strains could emerge or the illness would become endemic. Given this, Moderna shares are an easy addition to your portfolio for the coming year. is the source of this information.

30 August, 2021

Moderna Inc (MRNA) Stock Price and Forecast: Why is it probable that Moderna will continue to fall?

Moderna (MRNA) stock increased on Thursday as the omicron variant’s global distribution continued. This week, the WHO recorded a new high for covid-19 infections, and most wealthy nations with ample vaccine supply are currently administering booster injections. A fourth dosage of covid vaccinations will be administered in Israel.

Stock prediction for Moderna (MRNA)

In terms of infection rates, the news is bad, but it’s good news for vaccine producers. However, we are disappointed by Moderna’s failure to follow through on its December 20 declaration that their booster elicited a significant immunological response. MRNA stock soared significantly and was over 10% higher at one point, but then fell sharply and finished 6% down on the same day. Despite omicron rising and booster doses being extensively utilised, Moderna shares have not returned to those levels. This provides us with a bearish backdrop. The news is good, but the consequence is bad.

$234, $210, $188, and $157 are all good places to start. At $157, there is a lot of volume support. The 200-day and 21-day MAs, as well as the annual VWAP, provide resistance at $267 to $272. From the peak on December 20, $321 has been a stumbling block. is the source for this information.

10 December, 2021

Why Should You Buy Moderna Stock Every Time It Drops?

Moderna (NASDAQ:MRNA) cut its sales outlook when it released its quarterly results on November 4th. MRNA’s shares dropped from $350 to under $250 as a result of this. The introduction of omicron, a new Covid-19 derivative, has lately rekindled investor interest in the stock.

After increased worries of another wave, Moderna’s chances for 2022 have swung substantially to the positive. In light of the changes, how does this biotechnology company’s sales outlook change?

MRNA is on a downward trend.

Moderna’s buying enthusiasm slowed after the stock reached a high of $497.49 in August. In its third-quarter report, it reaffirmed its excellent fundamentals. Revenue reached $5 billion, with a $3.3 billion profit. It has $15 billion in cash on hand at the end of the third quarter.

Investors were alarmed when the corporation forecasted sales of $15 billion to $18 billion. In 2021, Moderna predicted that delivery dosages will decrease. Instead, it will be postponed until early 2022. Moderna must prioritise vaccine supply to low-income nations in order to combat and win the epidemic internationally. Africa is included in this. According to the media, the omicron type originated in Africa, prompting governments to impose travel bans on Africans.

In actuality, African experts were the first to notice the mutation. It’s possible that the strain came from somewhere else. The shortcoming in the policy reaffirms the importance of Moderna’s vaccine in bringing the epidemic to an end.

Stock Score for MRNA

Moderna has a high quality score for investors based on factors like return on invested capital. It also has a high value rating:

If demand for Moderna’s Covid-19 vaccine increases, the company’s growth score might improve. Booster injections are still needed over the world to protect people from the Delta strain.

Moderna’s Covid-19 vaccine isn’t a one-trick pony. It has billions of dollars in cash on hand to invest in developing mRNA therapies. Cancer, intratumoral immuno-oncology, localised regenerative therapies, systemic secretory and cell surface therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics are among the company’s eight active trials.

Moderna is only worth something because of its Covid-19 vaccine, according to the markets. The epidemic will eventually subside. Investing in Moderna for a long time will pay off for shareholders. Every quarter, the company’s cash flow improves. It announced a $1 billion stock repurchase programme over the following two years. In such time, shareholder returns will be higher. is the source of this information.

November 16, 2021

Moderna Stock Forecast: When is the Best Time to Buy MRNA?

Moderna (MRNA) climbed modestly on Monday, as the company sought to halt its recent slide. Even if the stock with the self-descriptive ticker had a great 2021, subsequent performance has been less than stellar, with investors losing trust or maybe withdrawing gains. Moderna is up 125 percent so far this year, but it has down about 30% in the previous month. The stock had risen substantially earlier in the day, so it was primed for a big drop once momentum shifted.

Stock prediction for Moderna (MRNA)

With a few dead cat bounces along the road, including Monday’s meagre 1.7 percent gain, this MRNA chart remains negative. When compared to the massive drops recorded last week, the change hardly registers on the chart. This appears to be a consolidation and continuation pattern to us. Only a breach of the 200-day moving average at $254 would convince us otherwise.

The area between $254 and $265 represents significant resistance. The annual Volume-Weighted Average Price, as well as the 200-day moving average (VWAP). It is presently where the 9-day moving average resides, even in the near term. If this zone is broken, the gap to $278 might be closed. Otherwise, the rise should continue, with $188.40 as an interim objective before $160 to $150 serving as a solid support region due to the high volume. is the source of this information.


Is Now the Right Time to Sell Moderna (MRNA) and Take Profits?

Moderna (MRNA) has outperformed the wider S&P 500 by more than 126 percent this year. The stock, meanwhile, remains 52 percent behind its 52-week high. After a dismal quarterly report, Moderna’s shares dropped roughly 35% in two trading days. Is it currently a good time to buy or sell Moderna stock based on its forecast?

Moderna’s stock is on the decline.

Moderna’s shares dropped more than 16 percent on Nov. 4 after the company lowered its COVID-19 vaccine sales prediction for this year and failed third-quarter profits and sales targets. Due to production issues and the company’s priority of vaccination supply to low-income countries, doses slated for delivery this year have been put back to early 2022. Moderna currently estimates that 700 million–800 million doses will be delivered in 2021, down from an earlier estimate of 800 million–1 billion.

Moderna now expects coronavirus vaccine sales to be between $15 billion and $20 billion in 2021, down from a previous projection of $20 billion. In addition, revenues of $17 billion to $22 billion are expected in 2022, according to the business. COVID-19 vaccine sales are expected to reach $36 billion in 2021 and $29 billion in 2022, according to Pfizer.

Moderna reported sales of $5 billion and earnings per share of $7.70 in the third quarter, below analysts’ average projections of $6.2 billion and $9.05, respectively. Moderna’s shares dropped 17% on Nov. 5 when competitor Pfizer announced that its COVID-19 tablet reduced hospitalizations and fatalities.

Forecast for Moderna’s stock in 2021

Moderna stock has an average target price of $223.86, which is 5.5 percent lower than its current price, according to MarketBeat. Six of the 16 analysts following Moderna advise “buy,” four advise “sell,” and six advise “hold.” Their maximum goal price of $395 is 67% higher than the current stock price, while their lowest target price of $86 is 64% lower.

On Nov. 5, Jefferies analyst Michael Yee maintained a “hold” recommendation on Moderna shares, lowering his target price to $325 from $375. Edward Tenthoff of Piper Sandler cut his price target from $445 to $348 and kept his “overweight” rating. Moderna’s mRNA pipeline, according to Tenthoff, is progressing. is the source of this information.

Disclaimer:The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.

More US Stocks Forecast Updates:

We will be happy to hear your thoughts

Leave a reply

Stock Consultant Bihar